30th Apr 2012 07:00
PuriCore plc
Director Dealing and Share Option Grant
PuriCore (LSE: PURI), the water-based clean technology company, announces today a director dealing and share option grant, in accordance with the Disclosure and Transparency Rules.
Director Dealing
The Company announces that on 27 April 2012 the following Director purchased shares in the Company, as set out below.
Name
| Number of shares purchased | Purchase price of shares | Shareholding following the acquisition | % of issued share capital |
Michael R.D. Ashton Non-Executive Chairman | 9,650 9,700 | 63p 64p |
19,350 |
0.08%
|
Senior Independent Non-Executive Director Share Option Grant
PuriCore also announces it has issued share options to the Company's Senior Independent Non-Executive Director as set forth below. The share options have an exercise price of 64.58p, which is 5% over the closing market price of the Company's ordinary shares on 27 April 2012, and a five-year term.
Name | Number of share options granted | Vesting |
James Walsh, PhD Senior Independent Non-Executive Director | 35,000 | ½ on 27 April 2013; ½ on 27 April 2014 |
Enquiries:
FTI Consulting
Susan Quigley
Victoria Foster Mitchell
+44 (0) 20 7831 3113
About PuriCore
PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including supermarketretail, medical device disinfection, and wound care. PuriCore's Solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Related Shares:
RLM.L